Plasma glycation levels are associated with severity in sepsis

European Journal of Clinical Investigation

Volumn 42, Issue 10, 2012, Pages 1055-1060

  Andrades, Michael Éverton ^a   Lorenzi, Rodrigo ^a   Nagai, Ryoji ^b   Moreira, José Cláudio Fonseca ^a   Ritter, Cristiane ^c   Dal Pizzol, Felipe ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b TOKAI UNIVERSITY   (Japan)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

(carboxymethy)lysine; Advanced glycation end products; N (carboxymethyl)lysine; Receptor for AGE; Sepsis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; N EPSILON (CARBOXYETHYL)LYSINE; N EPSILON (CARBOXYMETHYL)LYSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTENSIVE CARE; MALE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVOR;

CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY DISEASES; LYSINE; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SEPSIS;

EID: 84866269367     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02694.x     Document Type: Article

References (31)

1. Silva E, Pedro Mde A, Sogayar AC, Mohovic T, Silva CL, Janiszewski M et al. Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 2004;8:R251-60.
2. Webster NR, Galley HF. Immunomodulation in the critically ill. Br J Anaesth 2009;103:70-81.
3. Christaki E, Opal SM, Keith JC. Jr, Kessimian N, Palardy JE, Parejo NA et al. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. Shock 2011;35:492-8.
4. Min C, Kang E, Yu SH, Shinn SH, Kim YS. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract 1999;46:197-202.
5. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-8.
6. Busch M, Franke S, Ruster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010;40:742-55.
7. Andrades ME, Lorenzi R, Berger M, Guimaraes JA, Moreira JC, Dal-Pizzol F. Glycolaldehyde induces fibrinogen post-translational modification, delay in clotting and resistance to enzymatic digestion. Chem Biol Interact 2009;180:478-84.
8. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 1997;99:424-32.
9. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-13.
10. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999;55:389-99.
11. Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging. J Ren Nutr 2010;20:74-81.
12. McVerry BA, Fisher C, Hopp A, Huehns ER. Production of pseudodiabetic renal glomerular changes in mice after repeated injections of glucosylated proteins. Lancet 1980;1:738-40.
13. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
14. van Zoelen MA, Yang H, Florquin S, Meijers JC, Akira S, Arnold B et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009;31:280-4.
15. Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007;33:1347-53.
16. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
17. Imanaga Y, Sakata N, Takebayashi S, Matsunaga A, Sasaki J, Arakawa K et al. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 2000;150:343-55.
18. Valencia JV, Weldon SC, Quinn D, Kiers GH, DeGroot J, TeKoppele JM et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 2004;324:68-78.
19. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000;6:114-25.
20. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006;7:985-91.
21. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004;113:1641-50.
22. Susa Y, Masuda Y, Imaizumi H, Namiki A. Neutralization of receptor for advanced glycation end-products and high mobility group box-1 attenuates septic diaphragm dysfunction in rats with peritonitis. Crit Care Med 2009;37:2619-24.
23. Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008;147:79-83.
24. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010;2010:917108.
25. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ. Skin autofluorescence and glycemic variability. Diabetes Technol Ther 2010;12:581-5.
26. Kocsis AK, Szabolcs A, Hofner P, Takacs T, Farkas G, Boda K et al. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology 2009;9:383-91.
27. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628-34.
28. Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, van Ypersele de Strihou C et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998;53:416-22.
29. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996;39:149-60.
30. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-56.
31. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005;289:F645-59.